Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against fleas in cats, under field conditions

Abstract

Esafoxolaner is a purified afoxolaner enantiomer with insecticidal and acaricidal properties. It is combined with eprinomectin and praziquantel, nematodicidal and cestodicidal compounds, in a novel topical endectoparasiticide formulation for cats. This novel formulation was tested in four field studies, in the United States, Europe, Japan and Australia. In all studies, naturally flea-infested domestic cats were treated with the novel formulation at the label dose and conditions of use. The main objective, identical in the four studies, was to assess efficacy on fleas, based on comparison of mean number of fleas found on infested cats before and one month after treatment. Tolerance to the product was also evaluated in the four studies. Otherwise, the studies had some differences in their design and secondary objectives, for example testing for a reduction in flea infestation-related cutaneous signs, testing of one treatment or of three monthly treatments, and use of a positive control group. In the four studies, a total of 307 cats were treated with the novel formulation. The reduction of fleas one month after treatment was 97.7%, 98.8%, 100% and 99.7% in the United States, Europe, Japan and Australia, respectively. There were no significant health abnormalities attributed to treatment in any of the studies.

Efficacy of two endectoparasiticide products combining fipronil and (S)-methoprene or esafoxolaner with eprinomectin and praziquantel against fleas and intestinal helminths in cats naturally infested in Brazil

“…Broadline Ò has been used safely for several years [8] and was demonstrated to be efficacious against a broad spectrum of feline parasites, including fleas [1] and gastro-intestinal helminths [13,24]. NexGard Ò Combo was recently developed and registered in the European Union [9] and was demonstrated to be efficacious against fleas in experimental infestation studies conducted with isolates originating from France, South Africa and the USA [25], and in field studies with naturally infested cats from Europe, the USA and Australia [27], and against gastrointestinal helminths using induced and natural models of infection with isolates originating from Europe, North America and South Africa [12]. The safety of NexGard Ò Combo was also comprehensively demonstrated, namely in specific target animal safety studies [10,26].…”

Efficacy of a topical product combining esafoxolaner, eprinomectin and praziquantel against bedbug (Cimex lectularius) experimental infestations in cats

“…Afoxolaner was also demonstrated to be efficacious against flying hematophagous insects that do not live on the host, i.e. the sandfly (Phlebotomus perniciosus) [29], mosquito (Aedes aegypti) [23], stable fly (Stomoxys calcitrans) [36], kissing bug (Triatoma infestans) [24] and bedbug (C. lectularius) [2]. Eprinomectin, the nematocide compound, and praziquantel, the cestocide compound of the product, have insignificant and no potency on arthropods, respectively, when administered in combination with esafoxolaner (unpublished internal data).…”